FCGR1A KO cell lysate available now. KO validated by Next Generation Sequencing. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 99.99%.
Images
Key facts
- Cell type
- THP-1
- Species or organism
- Human
- Tissue
- Blood
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 99.99%
Alternative names
CD64 antigen, CD64A, CD64b, CD64c, FCG 1, FCGR1A, FCGR1B, FCGR1C, FCGR1_HUMAN, FCRIC, FLJ18345, Fc fragment of IgG high affinity Ia receptor, Fc fragment of IgG high affinity Ib receptor, Fc fragment of IgG high affinity Ic receptor, Fc fragment of IgG, high affinity Ia, receptor (CD64), Fc fragment of IgG, high affinity Ia, receptor for, Fc fragment of IgG, high affinity Ia, receptor for (CD64), Fc fragment of IgG, high affinity Ib, receptor (CD64), Fc fragment of IgG, high affinity Ib, receptor for, Fc fragment of IgG, high affinity Ic, receptor (CD64), Fc fragment of IgG, high affinity Ic, receptor (CD64), pseudogene, Fc fragment of IgG, high affinity Ic, receptor for, Fc gamma RIB, Fc gamma receptor, Fc gamma receptor I, Fc gamma receptor I A1, Fc gamma receptor I B2, Fc of IgG high affinity Ia receptor, Fc-gamma RI, Fc-gamma RIA, Fc-gamma RIC, FcRI, FcRIB, HFcgammaRIB, High affinity immunoglobulin gamma Fc receptor I, High affinity immunoglobulin gamma Fc receptor IB, IGFRB, IGFRC, IgG Fc receptor I, IgG Fc receptor IB, IgG Fc receptor IC, Immunoglobulin G Fc receptor I, Immunoglobulin G Fc receptor IB, Immunoglobulin G Fc receptor IC, MGC137713
What's included?
Recommended products
FCGR1A KO cell lysate available now. KO validated by Next Generation Sequencing. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 99.99%.
Key facts
- Cell type
- THP-1
- Species or organism
- Human
- Tissue
- Blood
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 99.99%
- Disease
- Acute Monocytic Leukemia
- Concentration
Properties
- Gene name
- FCGR1A
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Suspension
- Gender
- Male
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
CD64 also known as Fc gamma receptor 1a (FCGR1A) is a high-affinity receptor for the Fc region of immunoglobulin G (IgG). This receptor weighs approximately 72 kDa and is expressed on the surface of immune cells such as macrophages monocytes and activated neutrophils. CD64 protein plays an important role in immune responses by binding to antibodies and mediating processes such as phagocytosis and antibody-dependent cellular cytotoxicity (ADCC). Researchers often use anti-CD64 antibodies and CD64 markers to study its expression in various cellular contexts especially in flow cytometry.
- Biological function summary
CD64 expression involves the binding of IgG which serves as a pivotal mechanism to facilitate phagocytosis and clearance of opsonized pathogens. CD64 does not operate solely; it is part of a larger receptor family that includes other Fc gamma receptors like CD16 and CD32. The regulation of CD64 differs from its relatives due to its higher affinity for IgG. This attribute enables CD64 to play a more significant role in triggering immune responses especially during infections and inflammatory processes.
- Pathways
CD64 participates in the immune response pathway and is critical in the regulation of inflammatory responses. Key proteins interacting with CD64 in these pathways include the aforementioned CD16 and CD32 forming a network that ensures efficient immune system activation. The interaction with IgG and subsequent signal transduction underpin the receptor's functionality in these pathways harmonizing innate and adaptive immune responses.
- Associated diseases and disorders
CD64 expression correlates strongly with autoimmune disorders and inflammatory conditions. The receptor's role in orchestrating immune cell activation makes it relevant in diseases such as rheumatoid arthritis and sepsis. In rheumatoid arthritis CD64 interacts with immune complexes intensifying inflammation through enhancement of phagocytic activity. In sepsis increased CD64 marker expression on neutrophils can serve as a diagnostic indicator. Related proteins like CD16 and CD32 also participate in these disorders by modulating immune complex handling and cellular activation.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human FCGR1A knockout THP-1 cell lysate (ab275817)
Lane 1: Wild-type THP-1 cell lysate 20 μg
Lane 2: FCGR1A knockout THP-1 cell lysate 20 μg
Lane 3: U937 cell lysate 20 μg
Lane 4: HEK-293 cell lysate 20 μg
False colour image of Western blot: Anti-CD64 antibody [EPR4624] staining at 1/10000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-CD64 antibody [EPR4624] ab134073 was shown to bind specifically to CD64. A band was observed at 45-50/55-80 kDa in wild-type THP-1 cell lysates with no signal observed at this size in FCGR1A knockout cell line Human FCGR1A knockout THP-1 cell line ab275843 (knockout cell lysate ab275817). To generate this image, wild-type and FCGR1A knockout THP-1 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.All lanes: Western blot - Anti-CD64 antibody [EPR4624] (Anti-CD64 antibody [EPR4624] ab134073) at 1/10000 dilution
Lane 1: Wild-type THP-1 cell lysate at 20 µg
Lane 2: FCGR1A knockout THP-1 cell lysate at 20 µg
Lane 2: Western blot - Human FCGR1A knockout THP-1 cell line (Human FCGR1A knockout THP-1 cell line ab275843)
Lane 3: U937 cell lysate at 20 µg
Lane 4: HEK-293 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 43 kDa
Observed band size: 45 kDa, 45-50 kDa
Western blot - Human FCGR1A knockout THP-1 cell lysate (ab275817)
Lane 1: Wild-type THP-1 cell lysate 20 μg
Lane 2: FCGR1A knockout THP-1 cell lysate 20 μg
Lane 3: U937 cell lysate 20 μg
Lane 4: HEK-293 cell lysate 20 μg
False colour image of Western blot: Anti-CD64 antibody [EPR4623] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-CD64 antibody [EPR4623] ab109449 was shown to bind specifically to CD64. A band was observed at 45-50/55-80 kDa in wild-type THP-1 cell lysates with no signal observed at this size in FCGR1A knockout cell line Human FCGR1A knockout THP-1 cell line ab275843 (knockout cell lysate ab275817). To generate this image, wild-type and FCGR1A knockout THP-1 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.All lanes: Western blot - Anti-CD64 antibody [EPR4623] (Anti-CD64 antibody [EPR4623] ab109449) at 1/1000 dilution
Lane 1: Wild-type THP-1 cell lysate at 20 µg
Lane 2: FCGR1A knockout THP-1 cell lysate at 20 µg
Lane 2: Western blot - Human FCGR1A knockout THP-1 cell line (Human FCGR1A knockout THP-1 cell line ab275843)
Lane 3: U937 cell lysate at 20 µg
Lane 4: HEK-293 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 43 kDa
Observed band size: 45-50 kDa
Next Generation Sequencing - Human FCGR1A knockout THP-1 cell lysate (ab275817)
Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 99.99%
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com